Cancer Focus Fund LP is investing US$5 million in funding to support ISA Pharmaceuticals BV's ISA-103 in a first-in-human study for the treatment of uveal melanoma.
ISA Pharmaceuticals BV has closed a €26 million (US$30.76 million) funding round to advance its cancer immunotherapy product, ISA-101b, in the clinic, as the company aims to tackle the low response rates that hold back this therapeutic approach.
